Balyasny Asset Management
ALDX icon

Balyasny Asset Management’s Aldeyra Therapeutics ALDX Stock Holding History

Balyasny Asset Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,278
Closed -$56.3K – 2751
2024
Q4 		$56.3K Buy
+11,278
New +$57.9K ﹤0.01% 2633
2024
Q1 		– Sell
-18,720
Closed -$65.7K – 2573
2023
Q4 		$65.7K Sell
18,720
-48,860
-72% -$151K ﹤0.01% 2401
2023
Q3 		$451K Buy
67,580
+52,725
+355% +$391K ﹤0.01% 1789
2023
Q2 		$125K Sell
14,855
-11,624
-44% -$115K ﹤0.01% 2107
2023
Q1 		$263K Sell
26,479
-4,641
-15% -$32.8K ﹤0.01% 2164
2022
Q4 		$217K Buy
+31,120
New +$178K ﹤0.01% 2111
2021
Q2 		– Sell
-11,964
Closed -$142K – 1928
2021
Q1 		$142K Buy
+11,964
New +$138K ﹤0.01% 1605

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Balyasny Asset Management's ALDX Position: Q1 2025 in Review

Balyasny Asset Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2025, closing a stake of 11,278 shares — an estimated $56.3K sold.

Balyasny Asset Management first reported a position in ALDX in Q1 2021 and held it in 7 quarters. The position peaked at $451K in Q3 2023. 125 funds tracked by Wall St. Rank hold ALDX as of Q1 2025.

  • Balyasny Asset Management reported no remaining Aldeyra Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 11,278 Aldeyra Therapeutics shares in Q1 2025, an estimated $56.3K.
  • Balyasny Asset Management first reported a position in Aldeyra Therapeutics in Q1 2021 and held it in 7 quarters.
  • Balyasny Asset Management's Aldeyra Therapeutics position peaked at $451K in Q3 2023.
  • 125 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2025.

Based on Balyasny Asset Management's 13F filing for Q1 2025, filed 15 May 2025.